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Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and matrix- 
assisted laser desorption/ionization tandem time-of-flight mass spectrometry 
(MALDI-TOF/TOF-MS), incorporated with online database searching, were per- 
formed to investigate differential proteins of breast cancer and adjacent normal 
breast tissues. Considering that serum albumin is abundantly presented in nor- 
mal control samples, 15 differential spots detected in 11 out of 12 (91.7%) breast 
cancer samples were identified by online SIENA-2DPAGE database searching and 
MALDI-TOF/TOF-MS analysis. The results indicate that pathological changes of 
breast cancer are concerned with augmentation of substance metabolism, promo- 
tion of proteolytic activity, decline of activity of some inhibitors of enzymes, and so 
on. Some important proteins involved in the pathological process of breast cancer 
with changed expression may be useful biomarkers, such as alpha-l-antitrypsin, EF- 
l-beta, cathepsin D, TCTP, SMTSA, RPS12, and PSMA1, among which SMT3A, 
RPS12, and PSMAl were first reported for breast cancer in this study. 
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Introduction 
Breast cancer is a much commonly diagnosed cancer 
that is a leading cause of death for women ( I ) .  The 
tumorigenesis and progression toward malignancy of 
breast cancer are an extremely complex event involved 
in multiple agents, including hormones, genetic muta- 
tions, and various physical, chemical, and organismic 
agents from outside environment ( 2 , 3 ) .  Although 
breast cancer has been studied extensively during the 
past several decades, the underlying molecular mech- 
anism is currently not fully understood. Genes are 
the essential genetic materials to control cellular bi- 
ological characteristics while proteins perform varied 
and vital cellular functions in movement, and all cellu- 
lar behaviors in life can almost be interpreted in the 
protein level. In both category and abundance, the 
expressed proteins in breast cancer cells are different 
from those in normal breast cells. To elucidate the 
underlying molecular mechanism and search for new 
markers involved in clinical diagnosis, treatment, and 
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prognosis, in recent years many efforts have been 
made to study the differentially expressed proteins in 
breast cancer cells compared with normal controls by 
proteomic methods (4-6). The known genetic back- 
ground and consistent cellular composition are the 
main characteristics of cell lines distinguished from 
tissues; therefore, breast cancer cell lines are the most 
common samples used to make proteomic analysis of 
human breast cancer in the mechanism of tumorigen- 
esis, the effect and resistance of drugs, and prognosis 
(7-9). However, the growth and progression of breast 
tumor cells not only depend on their malignant po- 
tential but also depend on agents presented in the tu- 
mor microenvironment. There are interactions among 
cells and between cells and agents in their surround- 
ings. Proteins extracted from cell lines are only a part 
of the total proteins correlated to breast cancer. To 
make the best of obtaining all the information of pro- 
teins correlated to breast cancer, some other samples 
have been used for breast cancer proteomic analysis 
in recent several years, including tissue, serum, nipple 
aspirate fluid, interstitial cells, and so on ( I O - 1 3 ) .  
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In this study, two-dimensional polyacrylamide gel 
electrophoresis (2D-PAGE) and matrix-assisted laser 
desorption/ionization tandem time-of-flight mass 
spectrometry (MALDI-TOF/TOF-MS), incorporated 
with online database searching, were performed to in- 
vestigate differential proteins of breast cancer and ad- 
jacent normal breast tissues. The majority of PI val- 
ues of proteins are within 5.0-8.0, therefore, the linear 
immobilized pH gradient (IPG) strips of pH 5.0-8.0 
were used. 
Results 
More than 85% of the 2D gel images of all samples 
from both breast cancer and normal breast tissues 
were analyzed. As a result, about 1,000 spots from 
breast cancer tissue and 150 spots from normal breast 
tissue were detected (Figure 1). According to the 
image of sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE; Figure 2), we found that 
the protein content of the main strip (66.2 kDa) in 
normal control was two folds more than that in breast 
cancer sample. The majority of the proteins in nor- 
mal control was identified as serum albumin (10). 
The proportion of serum albumin to the total pro- 
tein in normal breast tissue was reckoned to be ap- 
proximately 80%. Furthermore, only about 400 spots 
were detected in breast cancer tissue when 50% load- 
ing content of samples was used in isoelectronic fo- 
cusing (IEF). Therefore, proteins were thought to be 
up-regulated in breast cancer tissue when their abun- 
dance was four folds more than that in normal con- 
trol. Proteins that increased less than four folds were 
thought to be possibly up-regulated. The other pro- 
teins with unchanged or decreased abundance were 
thought to be down-regulated in breast cancer tissue. 
’ Consequently, 15 differential spots were detected 
in 11 out of 12 (91.7%) breast cancer samples. These 
spots were then identified by searching in the online 
SIENA-2DPAGE database and MALDI-TOF/TOF- 
MS analysis. Among the 15 spots, 6 were up- 
regulated, 5 were down-regulated, and 4 (<4 folds) 
were possible to be upregulated in the infiltrating 
ductal carcinoma samples (Table 1). 
Discussion 
Tumorigenesis of breast cancer is a much more com- 
plicated event correlated with multiple agents in vivo 
and in vitro (14-16). Carcinomatous changes of cells 
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are tightly concerned with agents in microenviron- 
ment (17, 18). Changes of protein expressions in 
breast cancer tissues may play an important role in 
the tumorigenesis of breast cancer. Proteins from 
tissues are better to show cellular biological charac- 
teristics than those from cell lines (19). The struc- 
ture and function of cancer cells are different from 
those of normal cells, thus proteins expressed by can- 
cer cells are different from those by normal cells. 
Proteins from tissues comprise not only intracellu- 
lar proteins but also proteins secreted to the out- 
side of cells, and extracellular proteins may be se- 
creted from either non-breast cells or non-breast can- 
cer cells. Furthermore, in this study the normal 
breast tissues contained rich connective tissues but 
few breast ductal and lobular cells that presented non- 
active function in the non-lactation period of volun- 
teers with the age between 32-60 years (Figure 3). 
Therefore, many proteins with low abundance from 
normal breast cells were not detected. The results 
in both single SDS-PAGE gel (Figure 2) and 2D- 
PAGE gel (Figure 1) showed that proteins expressed 
in cancer tissue were extremely different from those 
in normal tissue. Since serum albumin is the majority 
of the total protein content in normal tissue sample, 
the loading content of each protein in normal control 
was quite different from that in cancer tissue sam- 
ple. Consequently, many proteins were not detected 
by 2D-PAGE, and differential protein spots in 2D- 
PAGE gels were not completely differential proteins 
in expression but maybe the same abundant protein 
that was possibly different in expression. On the basis 
of serum albumin being abundantly presented in nor- 
mal tissue, proteins were thought to be up-regulated 
in breast cancer tissue when their abundance was four 
folds more than that in normal control. Proteins 
with unchanged or decreased abundance were thought 
to be down-regulated in breast cancer tissue. Pro- 
teins that increased less than four folds in 2D-PAGE 
were thought to be possibly up-regulated because the 
difference may be not resulted from breast cancer. 
In this study, five proteins were down-regulated 
in breast cancer tissue, including serum albumin, 
immunoglobulin heavy chain gama, immunoglobulin 
light chain, apolipoproteinA-I (apoA-I) , and alpha- 
l-antitrypsin. Serum albumin, whose main function 
is the regulation of the colloidal osmotic pressure 
of blood, is the main protein of plasma. Both im- 
munoglobulin heavy chain gama and immunoglobulin 
light chain are components of seroglobulin. ApoA-I, 
which is the major protein of plasma high density 
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Fig. 1 The silver-staining 2D gels of proteins from normal breast tissue (A) and breast infiltrating ductal carcinoma 
tissue (B). 
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Fig. 2 The SDS-PAGE gel (coomassie brilliant blue R- 
sue; B: Breast infiltrating ductal carcinoma tissue; B*: 
Breast infiltrating ductal carcinoma tissue with two-fold 
loading content more than that in A or B. 
250-staining). M: Protein marker; A: Normal breast tis- B 
Fig. 3 The hematoxylin and eosin (H&E)-staining im- 
ages (100 folds) of normal breast tissue (A) and breast 
infiltrating ductal carcinoma tissue (B). 
Table 1 Protein Annotations from Breast Cancer and Normal Breast Tissues Identified by 2-DE* 
Group Spot ID MW PI Accession No. Spots identified 
Down- Pdl  67,502 5.98 PO2768 Serum albumin 
regulation Pd2 88,029 7.54 P99006 Immunoglobulin heavy chain gama 
Pd3 58,614 4.91 PO1009 Alphel-antitrypsin 
Pd4 23,989 5.12 PO2647 ApolipoproteinA-I (apoA-I) 
Pd5 25,705 6.41 P99007 Immunoglobulin light chain 
Probably Pd6 73,578 4.99 P11021 78 kDa Glucose-regulated protein (GRP78) 
Up-regulation (immunoglobin heavy chain binding protein) (BIP) 
Pd7 16,086 5.41 PO0441 Superoxide dismutase (SOD) 
Pd8 14,000 5.05 PO2766 Transthyretin (TBPA) 
Pmsl 21,072.5 7.63 P37802 Transgelin 2 
Up-regulation Pd9 29,514 4.57 P24534 Elongation factor 1-beta (EF-1-beta) 
PdlO 28,206 5.27 PO7339 Cathepsin D 
P d l l  21,788 4.87 P13693 Translationally controlled tumor protein (TCTP) 
Pms2 11,704 5.89 P55854 Small ubiquitin-related modifier 3 precursor 
Pms3 14,905 6.81 P63324 Ribosomal protein S12 (RPS12) 
Pms4 29,578.9 6.15 P25786 Proteasome subunit alpha type 1 (PSMA1) 
(SMT3A) (SUMO3) 
*Pd: Proteins identified by searching in the SIENA-2DPAGE database; Pms: Proteins identified by MALDI-TOF- 
TOF-MS; MW: molecular weight. 
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lipoprotein (HDL), participates in the reverse trans- 
port of cholesterol from tissues to the liver for excre- 
tion by promoting cholesterol efflux from tissues and 
by acting as a cofactor for the lecithin cholesterol acyl- 
transferase. The above four proteins are the exactly 
components of plasma proteins, and down-regulation 
of those proteins suggests that blood supply for cancer 
tissue is less than that for normal breast tissue. 
The concentrations of key proteins in diverse reg- 
ulatory pathways are controlled by post-translational 
ubiquitination and degradation by the 265 protea- 
some. Therefore, alterations in this proteolytic sys- 
tem are associated with pathologies of breast can- 
cer (20-22). The up-regulation of small ubiquitin- 
related modifier 3 precursor (SMT3A) and protea- 
some subunit alpha type 1 (PSMA1) indicate that 
the action of ubiquitin-proteasome system in breast 
cancer is strengthened. In addition, cathepsin D, 
which possesses acid proteases active in intracellu- 
lar protein breakdown, is currently thought to cor- 
relate to the pathogenesis of breast cancer (23-25). 
The over-expressin of cathepsin D in breast cancer 
may be involved in tissue infiltration. Proteolytic en- 
zymes could be very important in the spread of cancer, 
but the role of the body’s natural inhibitors of these 
enzymes in this process is rarely reported. Alpha- 
l-antitrypsin is an inhibitor of serine proteases. Its 
primary target is elastase, but it also has a moder- 
ate affinity for plasmin and thrombin. It was re- 
ported that the activity of alpha-l-antitrypsin was 
significantly lower in patients with breast cancer be- 
fore surgery than that in the controls, while after 
six months an increase in alpha-l-antitrypsin activ- 
ity was observed (24). Goodarzi and Turner (26)  re- 
ported that patients were unresponsive to treatment 
when high amounts of alpha-l-antitrypsin were ex- 
tracted, and the carbohydrate structure of alpha-l- 
antitrypsin was also altered in cancer. Therefore, the 
down-regulation of alpha-l-antitrypsin suggests that 
it might play an important role in pathological pro- 
gression in breast cancer. 
Malignant cells proliferate actively and substance 
metabolism is concomitantly enhanced. The up- 
regulation of elongation factor l-beta (EF-l-beta) and 
ribosomal protein S12 (RPS12) may be related to the 
promotion of protein synthesis. The elongation step of 
protein synthesis involves binding of aminoacyl-tRNA 
to the ribosomal A site, formation of a peptide bond, 
and translocation of the newly formed peptidyl-tRNA 
to the P site. The nucleotide exchange factor EF-1- 
beta plays a major role in the regulation of this pro- 
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cess by regenerating a GTP-bound EF-l-alpha that 
is necessary for each elongation cycle (27). However, 
the function of RPSl2 is currently unknown. Cheng et 
a1 (28,29)  found that the gene expression of RPSl2 
altered in the adjacent histopathologically “normal” 
cervical squamous epithelial tissue from cervical can- 
cer patients, and thought that RPS12 may be poten- 
tially useful as an early pre-transformation diagnostic 
marker for human cervical cancer. 
Translationally controlled tumor protein (TCTP) 
is involved in calcium binding and microtubule sta- 
bilization, and may be concerned with cell migra- 
tion. Some antihistaminic compounds and other 
pharmacological compounds with a related structure 
could kill tumor cells and significantly decrease the 
gene level of TCTP (30). Vercoutter-Edouart e t  a1 
(31)  also found that the up-regulation of TCTP oc- 
curred in MCF-7 human breast cancer cells induced 
by fibroblast growth factor-:! (FGF-2) stimulation. 
The up-regulation of TCTP in breast cancer indicates 
that TCTP might be a useful biomarker for breast 
cancer. 
In 2D-PAGE gels, there were many low abundant 
proteins, the majority of which were not detected 
when the loading content of samples in IEF was de- 
creased at 50%. Besides, serum albumin is abun- 
dantly presented in normal control sample, which may 
impact on experimental results. Therefore, only four 
proteins, namely 78 kDa glucose-regulated protein 
(GRP78), superoxide dismutase (SOD), transthyretin 
(TBPA), and transgelin 2, were identified and ana- 
lyzed. These four proteins increased in breast cancer 
but were less than four folds, thus they were possi- 
ble to be up-regulated in breast cancer. The alter- 
ation of transthyretin concentrations might compen- 
sate for changes in free thyroxine and thus the change 
of transthyretin may be involved in the substance 
metabolism in breast cancer (32) .  Over-expression 
of the GRP78 gene in malignant but not benign hu- 
man breast lesions (33)  with the changes of SOD 
and GRP78 might be correlated with stress reaction 
in cancer. Transgelin 2 was identified by MALDI- 
TOF/TOF-MS but its function has not been un- 
derstood. Shi et a1 (34)  found that transgelin 2 
mRNA was over-expressed in hepatocellular carci- 
noma (HCC) patients and thought that transgelin 2 
mRNA may be a diagnostic marker for HCC. The re- 
port related to the role of transgelin 2 in breast cancer 
has not been seen, and its function needs to be further 
verified. 
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Conclusion 
On the whole, breast cancer has a very complicated 
pathological process. In this study, we verified that 
pathological changes of breast cancer are concerned 
with augmentation of substance metabolism, promo- 
tion of proteolytic activity, decline of activity of some 
inhibitors of enzymes, and so on. Some important 
proteins with changes in expression are involved in 
the pathological process of breast cancer and may be 
useful biomarkers correlated to diagnosis, treatment 
effects, and prognosis for patients with breast cancer, 
such as alpha-l-antitrypsin, EF-l-beta, cathepsin D, 
TCTP, SMT3A, RPS12, and PSMA1. Among these 
proteins, SMT3A, RPS12, and PSMAl were first re- 
ported for breast cancer in this study. 
Materials and Methods 
Tissue specimens 
The fresh breast cancer tissues and adjacent normal 
breast tissues were obtained at excision of surgical 
operation from 12 volunteers between 32-60 years 
old with breast cancer at different clinical stages 
[TlNlMO (n=l), T2NlMO (n=4), T2N2MO (n=l), 
T2N3MO (n=2), T3N2MO (n=3), and T3N3M1 
(n=l)] at the Affiliated Hospital of North Sichuan 
Medial College, Nanchong, China. The tissues were 
frozen in -150°C super low temperature icebox 
(Revco, Asheville, USA) as soon as mastectomy was 
done. All samples were examined pathologically to 
obtain representative, viable, and non-necrotic tis- 
sues. The breast cancer was pathologically identified 
as infiltrating ductal carcinoma (Figure 3). 
Protein sample preparation 
Tissue protein extraction was accomplished by the 
ReadyPreTM Protein Extraction Kit (Total Protein) 
provided by Bio-Rad (Hercules, USA). The protein 
samples were then stored in aliquots of 200 pL at 
-80°C. To measure the concentration of the total pro- 
tein, the Bio-Rad RC DC Protein Assay was used. 
Since the protein samples contained substances like 
salts, nucleic acids, and lipids, all of which are known 
to interfere with IEF, the ReadyPreTM 2-D Cleanup 
Kit (Bio-Rad) was used to wash them away and to 
concentrate proteins in samples at the same time. Be- 
fore IEF, the concentration of protein samples was 
measured by using the Bio-Rad RC DC Protein As- 
say once more. 
2D-PAGE and gel staining 
Before 2D-PAGE, SDS-PAGE was firstly performed 
to preliminarily analyze the differences of proteins ex- 
pressed in breast cancer and normal tissues (Figure 
2), respectively. The loading content of protein sam- 
ples was 35 pg. The first-dimension IEF was per- 
formed with precast IPG strips (pH 5.0-8.0, linear 
pH IPG, 178x3.3x0.5 mm; Bio-Rad) using the focus- 
ing tray (Bio-Rad). The loading volume of protein 
samples was 320 pL (The loading content of protein 
samples was 500 pg stained with silver nitrate and 2 
mg stained with coomassie brilliant blue R-250 in each 
gel). IEF was carried out at 20°C with 50 pA/strip 
under the following conditions: Rehydration, 50 V, 
12 h, passive; SJ, 250 V, 25 min, slow; S2, 1,000 V, 2 
h, rapid; S3, 8,000 V, 5 h, linear; S4, 8,000 V, 60,000 
Vh, rapid; S5, 500 V, arbitrary. After IEF, it was 
necessary to equilibrate the IPG strips in a buffer 
containing SDS. The strips were first equilibrated in 
a buffer containing 6 M urea, 0.375 M Tris-HC1 (pH 
8.8), 2% SDS, 20% glycerol, and 2% (w/v) dithiothre- 
itol for 15 min, and then in a buffer containing 6 M 
urea, 0.375 M Tris-HC1 (pH 8.8), 2% SDS, 20% glyc- 
erol, and 2.5% (w/v) iodoacetamide for another 15 
min. The equilibrated strips were placed on top of the 
prepared 12% SDS polyacrylamide gels and sealed in 
place with 0.5% low-melt agarose (Sigma, St. Louis, 
USA). The SDS-PAGE was performed at a current of 
16 mA/gel for 30 min, then at another current of 24 
mA/gel at 4°C for about 5 h using PROTEANIIQ 
Xi Cell (Bio-Rad). 
After 2D-PAGE, the gels were stained with silver 
nitrate for analysis or with coomassie brilliant blue 
R-250 for preparative purposes. 
Scanning and image analysis 
The stained gels were scanned by UMAXpowerlook 
1120 (UMAX, Taiwan, China) and analyzed by using 
the PDQuest 7.0 software (Bio-Rad), and the results 
in differential protein spots in gels from breast cancer 
and adjacent normal tissues were determined. 
Identification of protein spots in gels 
The 2D-PAGE images were compared with the on- 
line counterparts of the SIENA-2DPAGE database 
(http://www.bio-mol.unisi.it/cgi-bin/mapl), and 
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then the correlative information of differential protein 
spots was acquired by clicking on a spot located in 
the same point in the corresponding 2D-PAGE maps 
of the SIENA-2DPAGE database. Some differential 
spots whose correlative information was not obtained 
from the SIENA-2DPAGE database was identified by 
MALDI-TOF/TOF-MS (35) .  
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